hCAP18 Levels and Vitamin D Deficiency in Chronic Kidney Disease
| Status: | Withdrawn |
|---|---|
| Conditions: | Other Indications, Renal Impairment / Chronic Kidney Disease, Gastrointestinal |
| Therapuetic Areas: | Gastroenterology, Nephrology / Urology, Other |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 4/21/2016 |
| Start Date: | December 2009 |
| End Date: | December 2014 |
The human immune system produces a protein called hCAP18 (also known as LL-37 or
cathelicidin). This protein is believed to help the body to fight infections. Studies
suggest that vitamin D may important in the production of hCAP18. This study is designed to
test the ability of two different forms of vitamin D to affect levels of hCAP18. Vitamin D
and hCAP18 levels will be measured during an initial visit. Individuals who are vitamin D
deficient will be randomly assigned to receive one of two forms of vitamin D for two weeks.
After this, follow-up levels will be measured.
cathelicidin). This protein is believed to help the body to fight infections. Studies
suggest that vitamin D may important in the production of hCAP18. This study is designed to
test the ability of two different forms of vitamin D to affect levels of hCAP18. Vitamin D
and hCAP18 levels will be measured during an initial visit. Individuals who are vitamin D
deficient will be randomly assigned to receive one of two forms of vitamin D for two weeks.
After this, follow-up levels will be measured.
Inclusion Criteria:
- Age 18-80
- Chronic Kidney Disease stage 3-4 (estimated glomerular filtration rate 15-60 ml/min)
Exclusion Criteria:
- 6 month history of hypercalcemia, hyperphosphatemia, or nephrolithiasis
- use of active vitamin D analog within 30 days
- functioning renal transplant
- Symptoms of active infection
- Granulomatous disorders
We found this trial at
1
site
Click here to add this to my saved trials
